Terms: = Brain cancer AND GNAS, RP4-543J19_4, 2778, ENSG00000087460, NESP55, NESP, GSP, POH, GNASXL, GNAS1, C20orf45, dJ309F20_1_1, SCG6, GPSA, Gnas, dJ806M20_3_3, XL2, MGC33735, XL, PHP1A, GSA, AHO, XLalphas, PHP1B AND Treatment
16740 results:
1. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract] [Full Text] [Related]
2. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
3. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
4. Preoperative walking exercise to improve prognosis in patients with supratentorial brain tumours after craniotomy: protocol for a randomised controlled trial.
Qu C; Cao Z; Zhou J; He S; Liu F; Liu Z
BMJ Open; 2024 May; 14(5):e080787. PubMed ID: 38754891
[TBL] [Abstract] [Full Text] [Related]
5. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment.
Lu IN; Cheung PF; Heming M; Thomas C; Giglio G; Leo M; Erdemir M; Wirth T; König S; Dambietz CA; Schroeter CB; Nelke C; Siveke JT; Ruck T; Klotz L; Haider C; Höftberger R; Kleinschnitz C; Wiendl H; Hagenacker T; Meyer Zu Horste G
Nat Commun; 2024 May; 15(1):4120. PubMed ID: 38750052
[TBL] [Abstract] [Full Text] [Related]
6. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Kurmasheva N; Said A; Wong B; Kinderman P; Han X; Rahimic AHF; Kress A; Carter-Timofte ME; Holm E; van der Horst D; Kollmann CF; Liu Z; Wang C; Hoang HD; Kovalenko E; Chrysopoulou M; Twayana KS; Ottosen RN; Svenningsen EB; Begnini F; Kiib AE; Kromm FEH; Weiss HJ; Di Carlo D; Muscolini M; Higgins M; van der Heijden M; Bardoul A; Tong T; Ozsvar A; Hou WH; Schack VR; Holm CK; Zheng Y; Ruzek M; Kalucka J; de la Vega L; Elgaher WAM; Korshoej AR; Lin R; Hiscott J; Poulsen TB; O'Neill LA; Roy DG; Rinschen MM; van Montfoort N; Diallo JS; Farin HF; Alain T; Olagnier D
Nat Commun; 2024 May; 15(1):4096. PubMed ID: 38750019
[TBL] [Abstract] [Full Text] [Related]
7. Zavegepant for Acute treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Suresh V; Bardhan M; Dave T; Shamim MA; Suresh D; Satish P; Dhakal B; Bhonsale A; Roy P; Padhi BK; Monteith T
Clin Neuropharmacol; 2024 May-Jun 01; 47(3):72-81. PubMed ID: 38743600
[TBL] [Abstract] [Full Text] [Related]
8. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
Suzuki S
Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
[TBL] [Abstract] [Full Text] [Related]
9. Transformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
[TBL] [Abstract] [Full Text] [Related]
10. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.
Kim BG; Lee SH; Jang Y; Kang S; Kang CM; Cho NH
J Transl Med; 2024 May; 22(1):453. PubMed ID: 38741142
[TBL] [Abstract] [Full Text] [Related]
11. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study.
da Silva EB; Vasquez MWM; de Almeida Teixeira BC; Neto MC; Sprenger F; Filho JLN; Almeida-Lopes L; Ramina R
Acta Neurochir (Wien); 2024 May; 166(1):212. PubMed ID: 38739282
[TBL] [Abstract] [Full Text] [Related]
12. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract] [Full Text] [Related]
13. Management of Autoimmune Encephalitis in a 7-Year-Old Child With CTLA-4 Haploinsufficiency and AMPA Receptor Antibodies: A Case Report.
Quaak MSW; Buijze MSJS; Verhoeven VJM; Vermont C; Buddingh EP; Heredia M; Samsom JN; Titulaer MJ; van Rossum AM; Kamphuis S; Neuteboom RF
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200254. PubMed ID: 38728609
[TBL] [Abstract] [Full Text] [Related]
14. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract] [Full Text] [Related]
15. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial.
Richard N; Arab-Hocine N; Vannier M; Leblanc-Boubchir R; Pelaquier A; Boruchowicz A; Musikas M; Amil M; Fumery M; Nahon S; Arotcarena R; Gelsi E; Maurin A; Hébuterne X; Savoye G
Age Ageing; 2024 May; 53(5):. PubMed ID: 38706390
[TBL] [Abstract] [Full Text] [Related]
17. Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines.
Stouffer M; Wandling E; Dickson L; Lin S; Duan H; Powe E; Jean-Louis D; Tiwari AK; Amos S
Cancer Rep (Hoboken); 2024 May; 7(5):e2051. PubMed ID: 38702989
[TBL] [Abstract] [Full Text] [Related]
18. Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
[TBL] [Abstract] [Full Text] [Related]
19. Early therapy evaluation of intra-arterial trastuzumab injection in a human breast cancer xenograft model using multiparametric MR imaging.
Kim BK; Kim B; You SH; Jang MS; Im GH; Kim KH
PLoS One; 2024; 19(5):e0300171. PubMed ID: 38701062
[TBL] [Abstract] [Full Text] [Related]
20. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
[Next]
